Mild COVID-19 Disease Course With Protracted Delirium in a Cognitively Impaired Patient Over the Age of 85 Years

2020 ◽  
Vol 22 (4) ◽  
Author(s):  
Sarah Payne ◽  
Adrienne Jankowski ◽  
Andrew Shutes-David ◽  
Katherine Ritchey ◽  
Debby W. Tsuang
Keyword(s):  
Cognitively Impaired ◽  
Disease Course ◽  
Impaired Patient

Use of PEG Tubes in the Cognitively Impaired Patient: Dispelling the Myths

2005 ◽  
Vol 20 (9) ◽  
pp. 722-733
Author(s):  
Marissa C. Galicia-Castillo ◽  
Caren McHenry Martin
Keyword(s):  
Cognitively Impaired ◽  
Impaired Patient

A Cognitively Impaired Patient Without a Surrogate

2011 ◽  
Vol 28 (8) ◽  
pp. 583-587
Author(s):  
Steven J. Baumrucker ◽  
Matt Stolick ◽  
Gerald M. Morris ◽  
Leslie Stilin ◽  
Gregg VandeKieft ◽  
...  
Keyword(s):  
Cognitively Impaired ◽  
Impaired Patient

scholarly journals 18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

2021 ◽  
Author(s):  
Alexis Moscoso ◽  
Jesús Silva-Rodríguez ◽  
Jose Manuel Aldrey ◽  
Julia Cortés ◽  
Juan Manuel Pías-Peleteiro ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
White Matter ◽  
Diffusion Tensor ◽  
Amyloid Β ◽  
Cerebral White Matter ◽  
Csf Biomarkers ◽  
Cognitively Impaired ◽  
Disease Course ◽  
Clinical Progression

Abstract Purpose Recent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer’s disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which demyelination, as measured with Aβ PET, contributes to AD progression remains unexplored. Methods Participants with concurrent 18F-florbetapir (FBP) PET, MRI, and cerebrospinal fluid (CSF) examinations were included (241 cognitively normal, 347 Aβ-positive cognitively impaired, and 207 Aβ-negative cognitively impaired subjects). A subset of these participants had also available diffusion tensor imaging (DTI) images (n = 195). We investigated cross-sectional associations of FBP retention in the white matter (WM) with MRI-based markers of WM degeneration, AD clinical progression, and fluid biomarkers. In longitudinal analyses, we used linear mixed models to assess whether FBP retention in normal-appearing WM (NAWM) predicted progression of WM hyperintensity (WMH) burden and clinical decline. Results In AD-continuum individuals, FBP retention in NAWM was (1) higher compared with WMH regions, (2) associated with DTI-based measures of WM integrity, and (3) associated with longitudinal progression of WMH burden. FBP uptake in WM decreased across the AD continuum and with increasingly abnormal CSF biomarkers of AD. Furthermore, FBP retention in the WM was associated with large-calibre axon degeneration as reflected by abnormal plasma neurofilament light chain levels. Low FBP uptake in NAWM predicted clinical decline in preclinical and prodromal AD, independent of demographics, global cortical Aβ, and WMH burden. Most of these associations were also observed in Aβ-negative cognitively impaired individuals. Conclusion These results support the hypothesis that FBP retention in the WM is myelin-related. Demyelination levels progressed across the AD continuum and were associated with clinical progression at early stages, suggesting that this pathologic process might be a relevant degenerative feature in the disease course.

Sign in / Sign up

Export Citation Format

Share Document